Influenza News and Research

Latest Influenza News and Research

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States.

16 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Infection control experts to convene at IPAC Canada conference

Infection control experts from across the country will meet in Victoria from June 14-17 at the Victoria Conference Centre for educational workshops and conference.

9 Jun 2015

St. Michael's Hospital researchers find novel method to combat flu virus

The flu kills hundreds of thousands of people around the world every year, yet there is essentially only one class of drugs to fight the ever-changing virus. Cases of flu resistant to this class of drugs have already been reported and researchers worry a completely new strain of flu could evolve, leading to a pandemic like the one in 1918 that killed approximately 50 million people.

8 Jun 2015

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine.

3 Jun 2015

Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

Scientists recognize that 90% of pathogens actually enter the body through the mucosa and secondly, we have evolved a mucosal defense system that can be used to defend against disease...

1 Jun 2015

BiondVax provides update on financial results for first quarter 2015

1 Jun 2015

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.

1 Jun 2015

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments.

28 May 2015

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people.

24 May 2015

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults.

21 May 2015

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis.

19 May 2015

New test could identify resistant tuberculosis faster

Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common.

From Oxford Gene Technology 14 May 2015

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

In a new study published in the Protein & Cell, Chen-Yu Zhang's group at Nanjing University reports that small non-coding RNAs in maternal food can transfer through placenta to regulate fetal gene expression.

14 May 2015

Bronchitis can cause pneumonia, says Loyola physician

When a cold has lasted too long or a cough is especially bothersome, it's important to see a medical professional.

14 May 2015

UCL-led team develops new technique to find resistant TB faster

The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team. This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks.

From Oxford Gene Technology 13 May 2015

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

13 May 2015

WHO calls on experts, social media to follow best practices in naming new human infectious diseases

WHO today called on scientists, national authorities and the media to follow best practices in naming new human infectious diseases to minimize unnecessary negative effects on nations, economies and people.

8 May 2015

WHO issues best practices for naming new human infectious diseases

The World Health Organization (WHO) today called on scientists, national authorities and the media to follow best practices in naming new human infectious diseases to minimize unnecessary negative effects on nations, economies and people...

8 May 2015

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK), a specialty biopharmaceutical company focused on the allergy market.

6 May 2015

Influenza News and Research

Latest Influenza News and Research

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Infection control experts to convene at IPAC Canada conference

St. Michael's Hospital researchers find novel method to combat flu virus

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

BiondVax provides update on financial results for first quarter 2015

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

Second-generation antibiotic shows promise against common bacterial infections

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

New test could identify resistant tuberculosis faster

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

Bronchitis can cause pneumonia, says Loyola physician

UCL-led team develops new technique to find resistant TB faster

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

WHO calls on experts, social media to follow best practices in naming new human infectious diseases

WHO issues best practices for naming new human infectious diseases

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Influenza News and Research

Latest Influenza News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in